Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
After taking individual risk factors into account, the risk for non-live birth was 29.7% with medication continuation versus 27.1% with non-continuation, a difference that was not deemed statistically significant
sulfonylureas) agents
Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands
Kjems, L
S., Khan, S
US$ 29.39
US$ 25.00
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 28.00
US$ 29.16
US$ 24.76
